Clinical Efficacy and Vaccine Potency Testing from a Single Platform

Analytics for coronavirus vaccines compatible with next generation vaccine platform technology

Accelerate coronavirus vaccine development by utilizing VaxArray’s rapid analytical platform to empower vaccine clinical efficacy studies, investigate population-level seroprevalence, or provide insight into vaccine manufacturing steps. VaxArray is a powerful platform technology, rapidly deployed to address the need of manufacturers developing life saving coronavirus vaccines. Use the VaxArray Coronavirus Spike Protein Assay for analysis of vaccine samples, or use the VaxArray Coronavirus SeroAssay for simultaneous measurements of antibody response to SARS-CoV-2 antigens and other endemic human coronaviruses.

Request more information

Benefits

• Fast and easy with <30 min hands on time and 2 hour time to results
• Quantitative determination of antibodies reactive to multiple coronavirus capture antigens including SARS-Cov-1, SARS-CoV-2, MERS, HKU1, 229E, NL63, and OC43
• High clinical specificity and low limits of detection
• Quantitative data enables higher quality research and better understanding of immunity
• Reduced hands on time and improved performance compared to ELISA
• SARS-CoV-2 Spike proteins recombinantly derived from multiple expression systems

Applications

• Preclinical animal studies
• Confirm pre-immunization status of clinical study participants
• Measure post-immunization immunogenicity
• Confirm induced cross-protection against other coronaviruses
• Seroprevalence research
• Characterization of therapeutic antibodies and convalescent serum